Gene Therapy On Cardiovascular Disease Market Research Report from 2023 forecast to 2029, by Manufacturers, Regions, Type and Application

The global Gene Therapy On Cardiovascular Disease market size was valued at USD 13 million in 2022 and is forecast to a readjusted size of USD 1073.1 million by 2029 with a CAGR of 87.1% during review period.

Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery. Although several conventional small-molecule treatments are available for common cardiovascular problems, gene therapy is a potential treatment option for acquired and inherited cardiovascular diseases that remain with unmet clinical needs.

Global key players of Gene Therapy On Cardiovascular Disease include Biogen, Novartis, Gilead Sciences, Sarepta Therapeutics, Alnylam Pharmaceuticals and Amgen, etc. Top three players occupy for a share about 76%. In terms of product, Non-Viral Gene Therapy is the largest segment, with a share over 100%. In terms of application, Vascular Disease is the largest market, with a share over 100%.

This report is a detailed and comprehensive analysis for global Gene Therapy On Cardiovascular Disease market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:

Global Gene Therapy On Cardiovascular Disease market size and forecasts, in consumption value ($ Million), 2018-2029
Global Gene Therapy On Cardiovascular Disease market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Gene Therapy On Cardiovascular Disease market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Gene Therapy On Cardiovascular Disease market shares of main players, in revenue ($ Million), 2018-2023

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Gene Therapy On Cardiovascular Disease
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace

This report profiles key players in the global Gene Therapy On Cardiovascular Disease market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

   Biogen
   Novartis
   Gilead Sciences
   Sarepta Therapeutics
   Alnylam Pharmaceuticals
   Amgen
   Spark Therapeutics
   Akcea Therapeutics
   bluebird bio
   Sunway Biotech
   SIBIONO
   AnGes
   Orchard Therapeutics
   Human Stem Cells Institute

   Viral Gene Therapy
   Non-Viral Gene Therapy

   Heart Disease
   Vascular Disease

   North America (United States, Canada, and Mexico)
   Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
   Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
   South America (Brazil, Argentina and Rest of South America)
   Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

What are the strengths of gene therapy in the cardiovascular disease market in 2025?

Gene therapy offers targeted treatment options that can address the underlying genetic causes of cardiovascular diseases, potentially leading to more effective outcomes compared to traditional therapies. Additionally, advancements in delivery mechanisms, such as viral vectors and nanoparticles, enhance the precision of treatment.

What weaknesses exist within the gene therapy market for cardiovascular diseases in 2025?

The high cost of development and treatment poses significant barriers to widespread adoption, making it less accessible to many patients. There are also concerns about the long-term efficacy and safety of gene therapies, which could hinder patient trust and willingness to undergo treatment.

What opportunities are present in the gene therapy market for cardiovascular diseases in 2025?

The growing prevalence of cardiovascular diseases, coupled with increased investment in biotechnology, creates a favorable environment for innovation in gene therapy. Collaborative efforts between academic institutions and pharmaceutical companies can accelerate research and development, leading to more breakthroughs in treatment options.

What threats could impact the gene therapy market for cardiovascular diseases in 2025?

Regulatory challenges and lengthy approval processes may delay the introduction of new therapies to the market. Additionally, competition from other emerging technologies, such as CRISPR and stem cell therapy, could overshadow gene therapy advancements, potentially limiting market growth.

How does the political environment affect the gene therapy market for cardiovascular diseases in 2025?

Government policies, including healthcare regulations and reimbursement frameworks, significantly impact the gene therapy market. Favorable policies supporting biotechnology innovation, funding, and fast-track approvals can accelerate market growth. However, political instability or changing healthcare policies could introduce uncertainty and slow progress.

What is the economic impact on gene therapy in the cardiovascular disease market in 2025?

Gene therapy treatments are costly, and economic factors such as healthcare budgets, insurance coverage, and affordability may limit their widespread adoption. However, economic recovery and increased investments in biotechnology could provide the necessary funding to develop and commercialize these therapies more effectively.

How do social factors influence the gene therapy market for cardiovascular diseases in 2025?

Public awareness and acceptance of gene therapy are crucial for market growth. As societal attitudes towards innovative treatments evolve, patients may become more open to these options. However, ethical concerns regarding genetic modifications and patient safety might still influence public opinion and regulatory scrutiny.

What technological advancements will impact gene therapy for cardiovascular diseases in 2025?

Advancements in gene editing technologies, such as CRISPR, and improvements in gene delivery systems are critical for the success of gene therapy. These innovations enhance precision, reduce side effects, and improve treatment efficacy, driving the market forward.

What environmental factors need to be considered in the gene therapy market for cardiovascular diseases in 2025?

Environmental sustainability in the production and disposal of gene therapy materials, as well as the ethical implications of genetic modifications, must be addressed. Increased focus on eco-friendly production processes and sustainable practices will play a role in shaping market growth.

How do legal factors influence the gene therapy market for cardiovascular diseases in 2025?

Strict regulatory requirements for clinical trials, patent laws, and intellectual property rights are key legal factors that influence the gene therapy market. Legal challenges related to patents or liability issues could delay the introduction of new therapies or increase development costs, potentially affecting market dynamics.

Who are the suppliers in the gene therapy for cardiovascular diseases market in 2025?

Suppliers include biotech companies, pharmaceutical manufacturers, academic research institutions, and contract research organizations (CROs) providing technologies, raw materials, research capabilities, and regulatory expertise to develop gene therapies.

What inputs are required for gene therapy in the cardiovascular disease market in 2025?

Key inputs include genetic materials, viral vectors or nanoparticles for delivery, gene-editing technologies like CRISPR, research data, clinical trial outcomes, and regulatory approvals for testing and commercialization.

What processes are involved in gene therapy development for cardiovascular diseases in 2025?

Processes include preclinical research, clinical trial design and execution, regulatory approval, manufacturing of gene therapy products, and post-market surveillance to ensure safety and efficacy.

Who are the customers of gene therapy in the cardiovascular disease market in 2025?

Customers are healthcare providers, including hospitals, clinics, and cardiologists, as well as patients suffering from cardiovascular diseases who are seeking advanced treatment options. Additionally, insurance companies and government health agencies are key stakeholders in reimbursement and accessibility.

What outputs are produced from gene therapy for cardiovascular diseases in 2025?

Outputs include FDA-approved gene therapy products, clinical trial data, patient outcomes reports, and treatment guidelines. These outputs contribute to improving patient health and advancing the adoption of gene therapies in cardiovascular care.

What is the threat of new entrants in the gene therapy for cardiovascular diseases market in 2025?

The threat of new entrants is moderate. While the high cost of research, development, and regulatory approval creates significant barriers to entry, advancements in gene-editing technologies and growing investments in biotech could enable new players to enter the market, particularly if they bring innovative approaches.

How intense is the rivalry among existing competitors in the gene therapy market for cardiovascular diseases in 2025?

Rivalry is expected to be high, as established biotech and pharmaceutical companies will compete to develop and commercialize gene therapies for cardiovascular diseases. The market is also likely to see increased collaborations and mergers as companies aim to capitalize on growth opportunities.

What is the bargaining power of suppliers in the gene therapy for cardiovascular diseases market in 2025?

Supplier power is high. Key suppliers provide specialized technologies and materials, such as viral vectors and CRISPR-based tools, which are essential for gene therapy development. The reliance on these unique inputs gives suppliers significant leverage in terms of pricing and availability.

What is the bargaining power of buyers in the gene therapy market for cardiovascular diseases in 2025?

The bargaining power of buyers is moderate. Healthcare providers and patients may have some influence due to the growing availability of treatment options, but the high cost and specialized nature of gene therapy limit the options available to most buyers. Insurers and governments also play a major role in determining accessibility and reimbursement.

What is the threat of substitute products in the gene therapy market for cardiovascular diseases in 2025?

The threat of substitutes is moderate. While traditional treatments for cardiovascular diseases, such as medication and surgery, remain widely used, gene therapy's potential to address the root causes of diseases gives it a unique advantage. However, emerging technologies, like stem cell therapies, could present alternative treatments in the future.

What are the key upstream factors affecting the gene therapy for cardiovascular diseases market in 2025?

Key upstream factors include the availability of advanced gene-editing technologies (like CRISPR), access to specialized delivery systems such as viral vectors, and collaboration with research institutions for preclinical studies. Funding for R&D, regulatory frameworks, and advancements in genetic understanding also play crucial roles.

What role do suppliers of raw materials play in the gene therapy market for cardiovascular diseases in 2025?

Suppliers of raw materials, including genetic materials, biological reagents, and delivery vehicles, are critical in ensuring the successful production of gene therapies. Their ability to provide high-quality and scalable products directly influences the cost and effectiveness of gene therapy treatments.

How do regulatory and clinical trial processes impact the upstream activities in gene therapy for cardiovascular diseases?

Regulatory approvals and clinical trial requirements shape upstream activities by setting the standards for safety and efficacy. The approval process can affect timelines, costs, and the availability of materials and technologies. Furthermore, clinical trial designs and outcomes drive demand for specific research and development inputs.

What are the challenges upstream stakeholders face in the gene therapy for cardiovascular diseases market?

Challenges include the high cost of developing new technologies and therapies, lengthy regulatory approval processes, and the complexity of scaling up production of gene therapies. Additionally, securing continuous funding for advanced research and meeting ethical considerations in genetic research add to the difficulty.

How does the upstream innovation in biotechnology impact the gene therapy market for cardiovascular diseases?

Innovation in biotechnology, such as improvements in gene-editing tools, new delivery mechanisms, and enhanced understanding of cardiovascular genetics, directly impacts the development of gene therapies. These innovations can reduce costs, improve the precision of therapies, and expedite their commercial availability.

What are the key midstream factors affecting the gene therapy for cardiovascular diseases market in 2025?

Midstream factors include the manufacturing process, distribution of gene therapy products, partnerships between biotech companies and contract manufacturing organizations (CMOs), and the need for quality control systems to ensure safety and consistency in gene therapy treatments.

How do manufacturing processes impact the gene therapy market for cardiovascular diseases in 2025?

Manufacturing processes are crucial, as gene therapies are complex to produce, requiring specialized facilities, high-level precision, and strict adherence to regulatory standards. Efficient production scales and cost-effective manufacturing techniques are needed to make therapies more accessible to the market.

What role do logistics and distribution play in the gene therapy for cardiovascular diseases market?

Logistics and distribution are vital for the timely and safe delivery of gene therapies. This includes ensuring that therapies are transported under controlled conditions, which is especially critical given the sensitive nature of biological products. Additionally, establishing strong distribution networks is key to reaching healthcare providers globally.

What challenges are faced in the midstream phase of gene therapy development for cardiovascular diseases?

Challenges include high production costs due to the complexity of gene therapies, ensuring scalability while maintaining product quality, and managing the cold-chain logistics for transporting sensitive products. Moreover, ensuring timely and widespread distribution remains difficult due to regulatory and infrastructure constraints.

How does collaboration with contract manufacturing organizations (CMOs) affect the midstream activities in the gene therapy market?

Collaboration with CMOs allows gene therapy developers to access specialized manufacturing expertise, reduce production costs, and scale up manufacturing capacity quickly. CMOs help mitigate the challenges of facility investment and regulatory compliance, providing flexibility to meet growing market demand.

What are the key downstream factors affecting the gene therapy for cardiovascular diseases market in 2025?

Downstream factors include the commercialization of gene therapies, pricing strategies, marketing efforts, healthcare provider adoption, patient access, and reimbursement policies. Additionally, the involvement of insurance companies and the integration of gene therapies into existing treatment protocols are important for market penetration.

How does pricing impact the downstream activities in the gene therapy market for cardiovascular diseases?

Pricing plays a critical role in the downstream phase, as the high cost of gene therapies may limit accessibility for many patients. Companies must balance the need for profitability with the desire to ensure that treatments are affordable and covered by insurance providers to enhance adoption rates.

What role do healthcare providers play in the downstream phase of gene therapy for cardiovascular diseases?

Healthcare providers are crucial for the downstream market, as they influence the acceptance and prescription of gene therapies. Their understanding of the benefits, risks, and outcomes of gene therapy treatments impacts patient choice and the overall success of gene therapies in clinical practice.

What challenges exist in the downstream phase of gene therapy development for cardiovascular diseases?

Challenges include limited awareness and understanding of gene therapies among healthcare providers, high treatment costs leading to insurance coverage issues, and ensuring patient access to specialized care. Regulatory hurdles around reimbursement and the integration of gene therapies into existing healthcare systems also pose significant challenges.

How does patient access affect the success of gene therapy in the cardiovascular disease market?

Patient access is a major downstream concern. The availability of gene therapies depends on geographic location, healthcare infrastructure, and the affordability of treatments. Inadequate access can lead to limited market uptake, even if the therapy is clinically effective, impacting the overall success of gene therapy in the market.

Chapter 1, to describe Gene Therapy On Cardiovascular Disease product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Gene Therapy On Cardiovascular Disease, with revenue, gross margin and global market share of Gene Therapy On Cardiovascular Disease from 2018 to 2023.
Chapter 3, the Gene Therapy On Cardiovascular Disease competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Gene Therapy On Cardiovascular Disease market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Gene Therapy On Cardiovascular Disease.
Chapter 13, to describe Gene Therapy On Cardiovascular Disease research findings and conclusion.

1 Market Overview

   1.1 Product Overview and Scope of Gene Therapy On Cardiovascular Disease
   1.2 Market Estimation Caveats and Base Year
   1.3 Classification of Gene Therapy On Cardiovascular Disease by Type
       1.3.1 Overview: Global Gene Therapy On Cardiovascular Disease Market Size by Type: 2018 Versus 2022 Versus 2029
       1.3.2 Global Gene Therapy On Cardiovascular Disease Consumption Value Market Share by Type in 2022
       1.3.3 Viral Gene Therapy
       1.3.4 Non-Viral Gene Therapy
   1.4 Global Gene Therapy On Cardiovascular Disease Market by Application
       1.4.1 Overview: Global Gene Therapy On Cardiovascular Disease Market Size by Application: 2018 Versus 2022 Versus 2029
       1.4.2 Heart Disease
       1.4.3 Vascular Disease
   1.5 Global Gene Therapy On Cardiovascular Disease Market Size & Forecast
   1.6 Global Gene Therapy On Cardiovascular Disease Market Size and Forecast by Region
       1.6.1 Global Gene Therapy On Cardiovascular Disease Market Size by Region: 2018 VS 2022 VS 2029
       1.6.2 Global Gene Therapy On Cardiovascular Disease Market Size by Region, (2018-2029)
       1.6.3 North America Gene Therapy On Cardiovascular Disease Market Size and Prospect (2018-2029)
       1.6.4 Europe Gene Therapy On Cardiovascular Disease Market Size and Prospect (2018-2029)
       1.6.5 Asia-Pacific Gene Therapy On Cardiovascular Disease Market Size and Prospect (2018-2029)
       1.6.6 South America Gene Therapy On Cardiovascular Disease Market Size and Prospect (2018-2029)
       1.6.7 Middle East and Africa Gene Therapy On Cardiovascular Disease Market Size and Prospect (2018-2029)

2 Company Profiles

   2.1 Biogen
       2.1.1 Biogen Details
       2.1.2 Biogen Major Business
       2.1.3 Biogen Gene Therapy On Cardiovascular Disease Product and Solutions
       2.1.4 Biogen Gene Therapy On Cardiovascular Disease Revenue, Gross Margin and Market Share (2018-2023)
       2.1.5 Biogen Recent Developments and Future Plans
   2.2 Novartis
       2.2.1 Novartis Details
       2.2.2 Novartis Major Business
       2.2.3 Novartis Gene Therapy On Cardiovascular Disease Product and Solutions
       2.2.4 Novartis Gene Therapy On Cardiovascular Disease Revenue, Gross Margin and Market Share (2018-2023)
       2.2.5 Novartis Recent Developments and Future Plans
   2.3 Gilead Sciences
       2.3.1 Gilead Sciences Details
       2.3.2 Gilead Sciences Major Business
       2.3.3 Gilead Sciences Gene Therapy On Cardiovascular Disease Product and Solutions
       2.3.4 Gilead Sciences Gene Therapy On Cardiovascular Disease Revenue, Gross Margin and Market Share (2018-2023)
       2.3.5 Gilead Sciences Recent Developments and Future Plans
   2.4 Sarepta Therapeutics
       2.4.1 Sarepta Therapeutics Details
       2.4.2 Sarepta Therapeutics Major Business
       2.4.3 Sarepta Therapeutics Gene Therapy On Cardiovascular Disease Product and Solutions
       2.4.4 Sarepta Therapeutics Gene Therapy On Cardiovascular Disease Revenue, Gross Margin and Market Share (2018-2023)
       2.4.5 Sarepta Therapeutics Recent Developments and Future Plans
   2.5 Alnylam Pharmaceuticals
       2.5.1 Alnylam Pharmaceuticals Details
       2.5.2 Alnylam Pharmaceuticals Major Business
       2.5.3 Alnylam Pharmaceuticals Gene Therapy On Cardiovascular Disease Product and Solutions
       2.5.4 Alnylam Pharmaceuticals Gene Therapy On Cardiovascular Disease Revenue, Gross Margin and Market Share (2018-2023)
       2.5.5 Alnylam Pharmaceuticals Recent Developments and Future Plans
   2.6 Amgen
       2.6.1 Amgen Details
       2.6.2 Amgen Major Business
       2.6.3 Amgen Gene Therapy On Cardiovascular Disease Product and Solutions
       2.6.4 Amgen Gene Therapy On Cardiovascular Disease Revenue, Gross Margin and Market Share (2018-2023)
       2.6.5 Amgen Recent Developments and Future Plans
   2.7 Spark Therapeutics
       2.7.1 Spark Therapeutics Details
       2.7.2 Spark Therapeutics Major Business
       2.7.3 Spark Therapeutics Gene Therapy On Cardiovascular Disease Product and Solutions
       2.7.4 Spark Therapeutics Gene Therapy On Cardiovascular Disease Revenue, Gross Margin and Market Share (2018-2023)
       2.7.5 Spark Therapeutics Recent Developments and Future Plans
   2.8 Akcea Therapeutics
       2.8.1 Akcea Therapeutics Details
       2.8.2 Akcea Therapeutics Major Business
       2.8.3 Akcea Therapeutics Gene Therapy On Cardiovascular Disease Product and Solutions
       2.8.4 Akcea Therapeutics Gene Therapy On Cardiovascular Disease Revenue, Gross Margin and Market Share (2018-2023)
       2.8.5 Akcea Therapeutics Recent Developments and Future Plans
   2.9 bluebird bio
       2.9.1 bluebird bio Details
       2.9.2 bluebird bio Major Business
       2.9.3 bluebird bio Gene Therapy On Cardiovascular Disease Product and Solutions
       2.9.4 bluebird bio Gene Therapy On Cardiovascular Disease Revenue, Gross Margin and Market Share (2018-2023)
       2.9.5 bluebird bio Recent Developments and Future Plans
   2.10 Sunway Biotech 
       2.10.1 Sunway Biotech Details
       2.10.2 Sunway Biotech Major Business
       2.10.3 Sunway Biotech Gene Therapy On Cardiovascular Disease Product and Solutions
       2.10.4 Sunway Biotech Gene Therapy On Cardiovascular Disease Revenue, Gross Margin and Market Share (2018-2023)
       2.10.5 Sunway Biotech Recent Developments and Future Plans
   2.11 SIBIONO
       2.11.1 SIBIONO Details
       2.11.2 SIBIONO Major Business
       2.11.3 SIBIONO Gene Therapy On Cardiovascular Disease Product and Solutions
       2.11.4 SIBIONO Gene Therapy On Cardiovascular Disease Revenue, Gross Margin and Market Share (2018-2023)
       2.11.5 SIBIONO Recent Developments and Future Plans
   2.12 AnGes
       2.12.1 AnGes Details
       2.12.2 AnGes Major Business
       2.12.3 AnGes Gene Therapy On Cardiovascular Disease Product and Solutions
       2.12.4 AnGes Gene Therapy On Cardiovascular Disease Revenue, Gross Margin and Market Share (2018-2023)
       2.12.5 AnGes Recent Developments and Future Plans
   2.13 Orchard Therapeutics
       2.13.1 Orchard Therapeutics Details
       2.13.2 Orchard Therapeutics Major Business
       2.13.3 Orchard Therapeutics Gene Therapy On Cardiovascular Disease Product and Solutions
       2.13.4 Orchard Therapeutics Gene Therapy On Cardiovascular Disease Revenue, Gross Margin and Market Share (2018-2023)
       2.13.5 Orchard Therapeutics Recent Developments and Future Plans
   2.14 Human Stem Cells Institute
       2.14.1 Human Stem Cells Institute Details
       2.14.2 Human Stem Cells Institute Major Business
       2.14.3 Human Stem Cells Institute Gene Therapy On Cardiovascular Disease Product and Solutions
       2.14.4 Human Stem Cells Institute Gene Therapy On Cardiovascular Disease Revenue, Gross Margin and Market Share (2018-2023)
       2.14.5 Human Stem Cells Institute Recent Developments and Future Plans

3 Market Competition, by Players

   3.1 Global Gene Therapy On Cardiovascular Disease Revenue and Share by Players (2018-2023)
   3.2 Market Share Analysis (2022)
       3.2.1 Market Share of Gene Therapy On Cardiovascular Disease by Company Revenue
       3.2.2 Top 3 Gene Therapy On Cardiovascular Disease Players Market Share in 2022
       3.2.3 Top 6 Gene Therapy On Cardiovascular Disease Players Market Share in 2022
   3.3 Gene Therapy On Cardiovascular Disease Market: Overall Company Footprint Analysis
       3.3.1 Gene Therapy On Cardiovascular Disease Market: Region Footprint
       3.3.2 Gene Therapy On Cardiovascular Disease Market: Company Product Type Footprint
       3.3.3 Gene Therapy On Cardiovascular Disease Market: Company Product Application Footprint
   3.4 New Market Entrants and Barriers to Market Entry
   3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

   4.1 Global Gene Therapy On Cardiovascular Disease Consumption Value and Market Share by Type (2018-2023)
   4.2 Global Gene Therapy On Cardiovascular Disease Market Forecast by Type (2024-2029)

5 Market Size Segment by Application

   5.1 Global Gene Therapy On Cardiovascular Disease Consumption Value Market Share by Application (2018-2023)
   5.2 Global Gene Therapy On Cardiovascular Disease Market Forecast by Application (2024-2029)

6 North America

   6.1 North America Gene Therapy On Cardiovascular Disease Consumption Value by Type (2018-2029)
   6.2 North America Gene Therapy On Cardiovascular Disease Consumption Value by Application (2018-2029)
   6.3 North America Gene Therapy On Cardiovascular Disease Market Size by Country
       6.3.1 North America Gene Therapy On Cardiovascular Disease Consumption Value by Country (2018-2029)
       6.3.2 United States Gene Therapy On Cardiovascular Disease Market Size and Forecast (2018-2029)
       6.3.3 Canada Gene Therapy On Cardiovascular Disease Market Size and Forecast (2018-2029)
       6.3.4 Mexico Gene Therapy On Cardiovascular Disease Market Size and Forecast (2018-2029)

7 Europe

   7.1 Europe Gene Therapy On Cardiovascular Disease Consumption Value by Type (2018-2029)
   7.2 Europe Gene Therapy On Cardiovascular Disease Consumption Value by Application (2018-2029)
   7.3 Europe Gene Therapy On Cardiovascular Disease Market Size by Country
       7.3.1 Europe Gene Therapy On Cardiovascular Disease Consumption Value by Country (2018-2029)
       7.3.2 Germany Gene Therapy On Cardiovascular Disease Market Size and Forecast (2018-2029)
       7.3.3 France Gene Therapy On Cardiovascular Disease Market Size and Forecast (2018-2029)
       7.3.4 United Kingdom Gene Therapy On Cardiovascular Disease Market Size and Forecast (2018-2029)
       7.3.5 Russia Gene Therapy On Cardiovascular Disease Market Size and Forecast (2018-2029)
       7.3.6 Italy Gene Therapy On Cardiovascular Disease Market Size and Forecast (2018-2029)

8 Asia-Pacific

   8.1 Asia-Pacific Gene Therapy On Cardiovascular Disease Consumption Value by Type (2018-2029)
   8.2 Asia-Pacific Gene Therapy On Cardiovascular Disease Consumption Value by Application (2018-2029)
   8.3 Asia-Pacific Gene Therapy On Cardiovascular Disease Market Size by Region
       8.3.1 Asia-Pacific Gene Therapy On Cardiovascular Disease Consumption Value by Region (2018-2029)
       8.3.2 China Gene Therapy On Cardiovascular Disease Market Size and Forecast (2018-2029)
       8.3.3 Japan Gene Therapy On Cardiovascular Disease Market Size and Forecast (2018-2029)
       8.3.4 South Korea Gene Therapy On Cardiovascular Disease Market Size and Forecast (2018-2029)
       8.3.5 India Gene Therapy On Cardiovascular Disease Market Size and Forecast (2018-2029)
       8.3.6 Southeast Asia Gene Therapy On Cardiovascular Disease Market Size and Forecast (2018-2029)
       8.3.7 Australia Gene Therapy On Cardiovascular Disease Market Size and Forecast (2018-2029)

9 South America

   9.1 South America Gene Therapy On Cardiovascular Disease Consumption Value by Type (2018-2029)
   9.2 South America Gene Therapy On Cardiovascular Disease Consumption Value by Application (2018-2029)
   9.3 South America Gene Therapy On Cardiovascular Disease Market Size by Country
       9.3.1 South America Gene Therapy On Cardiovascular Disease Consumption Value by Country (2018-2029)
       9.3.2 Brazil Gene Therapy On Cardiovascular Disease Market Size and Forecast (2018-2029)
       9.3.3 Argentina Gene Therapy On Cardiovascular Disease Market Size and Forecast (2018-2029)

10 Middle East & Africa

   10.1 Middle East & Africa Gene Therapy On Cardiovascular Disease Consumption Value by Type (2018-2029)
   10.2 Middle East & Africa Gene Therapy On Cardiovascular Disease Consumption Value by Application (2018-2029)
   10.3 Middle East & Africa Gene Therapy On Cardiovascular Disease Market Size by Country
       10.3.1 Middle East & Africa Gene Therapy On Cardiovascular Disease Consumption Value by Country (2018-2029)
       10.3.2 Turkey Gene Therapy On Cardiovascular Disease Market Size and Forecast (2018-2029)
       10.3.3 Saudi Arabia Gene Therapy On Cardiovascular Disease Market Size and Forecast (2018-2029)
       10.3.4 UAE Gene Therapy On Cardiovascular Disease Market Size and Forecast (2018-2029)

11 Market Dynamics

   11.1 Gene Therapy On Cardiovascular Disease Market Drivers
   11.2 Gene Therapy On Cardiovascular Disease Market Restraints
   11.3 Gene Therapy On Cardiovascular Disease Trends Analysis
   11.4 Porters Five Forces Analysis
       11.4.1 Threat of New Entrants
       11.4.2 Bargaining Power of Suppliers
       11.4.3 Bargaining Power of Buyers
       11.4.4 Threat of Substitutes
       11.4.5 Competitive Rivalry
   11.5 Influence of COVID-19 and Russia-Ukraine War
       11.5.1 Influence of COVID-19
       11.5.2 Influence of Russia-Ukraine War

12 Industry Chain Analysis

   12.1 Gene Therapy On Cardiovascular Disease Industry Chain
   12.2 Gene Therapy On Cardiovascular Disease Upstream Analysis
   12.3 Gene Therapy On Cardiovascular Disease Midstream Analysis
   12.4 Gene Therapy On Cardiovascular Disease Downstream Analysis

13 Research Findings and Conclusion

14 Appendix

   14.1 Methodology
   14.2 Research Process and Data Source
   14.3 Disclaimer

List of Tables

   Table 1. Global Gene Therapy On Cardiovascular Disease Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
   Table 2. Global Gene Therapy On Cardiovascular Disease Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
   Table 3. Global Gene Therapy On Cardiovascular Disease Consumption Value by Region (2018-2023) & (USD Million)
   Table 4. Global Gene Therapy On Cardiovascular Disease Consumption Value by Region (2024-2029) & (USD Million)
   Table 5. Biogen Company Information, Head Office, and Major Competitors
   Table 6. Biogen Major Business
   Table 7. Biogen Gene Therapy On Cardiovascular Disease Product and Solutions
   Table 8. Biogen Gene Therapy On Cardiovascular Disease Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 9. Biogen Recent Developments and Future Plans
   Table 10. Novartis Company Information, Head Office, and Major Competitors
   Table 11. Novartis Major Business
   Table 12. Novartis Gene Therapy On Cardiovascular Disease Product and Solutions
   Table 13. Novartis Gene Therapy On Cardiovascular Disease Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 14. Novartis Recent Developments and Future Plans
   Table 15. Gilead Sciences Company Information, Head Office, and Major Competitors
   Table 16. Gilead Sciences Major Business
   Table 17. Gilead Sciences Gene Therapy On Cardiovascular Disease Product and Solutions
   Table 18. Gilead Sciences Gene Therapy On Cardiovascular Disease Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 19. Gilead Sciences Recent Developments and Future Plans
   Table 20. Sarepta Therapeutics Company Information, Head Office, and Major Competitors
   Table 21. Sarepta Therapeutics Major Business
   Table 22. Sarepta Therapeutics Gene Therapy On Cardiovascular Disease Product and Solutions
   Table 23. Sarepta Therapeutics Gene Therapy On Cardiovascular Disease Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 24. Sarepta Therapeutics Recent Developments and Future Plans
   Table 25. Alnylam Pharmaceuticals Company Information, Head Office, and Major Competitors
   Table 26. Alnylam Pharmaceuticals Major Business
   Table 27. Alnylam Pharmaceuticals Gene Therapy On Cardiovascular Disease Product and Solutions
   Table 28. Alnylam Pharmaceuticals Gene Therapy On Cardiovascular Disease Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 29. Alnylam Pharmaceuticals Recent Developments and Future Plans
   Table 30. Amgen Company Information, Head Office, and Major Competitors
   Table 31. Amgen Major Business
   Table 32. Amgen Gene Therapy On Cardiovascular Disease Product and Solutions
   Table 33. Amgen Gene Therapy On Cardiovascular Disease Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 34. Amgen Recent Developments and Future Plans
   Table 35. Spark Therapeutics Company Information, Head Office, and Major Competitors
   Table 36. Spark Therapeutics Major Business
   Table 37. Spark Therapeutics Gene Therapy On Cardiovascular Disease Product and Solutions
   Table 38. Spark Therapeutics Gene Therapy On Cardiovascular Disease Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 39. Spark Therapeutics Recent Developments and Future Plans
   Table 40. Akcea Therapeutics Company Information, Head Office, and Major Competitors
   Table 41. Akcea Therapeutics Major Business
   Table 42. Akcea Therapeutics Gene Therapy On Cardiovascular Disease Product and Solutions
   Table 43. Akcea Therapeutics Gene Therapy On Cardiovascular Disease Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 44. Akcea Therapeutics Recent Developments and Future Plans
   Table 45. bluebird bio Company Information, Head Office, and Major Competitors
   Table 46. bluebird bio Major Business
   Table 47. bluebird bio Gene Therapy On Cardiovascular Disease Product and Solutions
   Table 48. bluebird bio Gene Therapy On Cardiovascular Disease Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 49. bluebird bio Recent Developments and Future Plans
   Table 50. Sunway Biotech Company Information, Head Office, and Major Competitors
   Table 51. Sunway Biotech Major Business
   Table 52. Sunway Biotech Gene Therapy On Cardiovascular Disease Product and Solutions
   Table 53. Sunway Biotech Gene Therapy On Cardiovascular Disease Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 54. Sunway Biotech Recent Developments and Future Plans
   Table 55. SIBIONO Company Information, Head Office, and Major Competitors
   Table 56. SIBIONO Major Business
   Table 57. SIBIONO Gene Therapy On Cardiovascular Disease Product and Solutions
   Table 58. SIBIONO Gene Therapy On Cardiovascular Disease Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 59. SIBIONO Recent Developments and Future Plans
   Table 60. AnGes Company Information, Head Office, and Major Competitors
   Table 61. AnGes Major Business
   Table 62. AnGes Gene Therapy On Cardiovascular Disease Product and Solutions
   Table 63. AnGes Gene Therapy On Cardiovascular Disease Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 64. AnGes Recent Developments and Future Plans
   Table 65. Orchard Therapeutics Company Information, Head Office, and Major Competitors
   Table 66. Orchard Therapeutics Major Business
   Table 67. Orchard Therapeutics Gene Therapy On Cardiovascular Disease Product and Solutions
   Table 68. Orchard Therapeutics Gene Therapy On Cardiovascular Disease Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 69. Orchard Therapeutics Recent Developments and Future Plans
   Table 70. Human Stem Cells Institute Company Information, Head Office, and Major Competitors
   Table 71. Human Stem Cells Institute Major Business
   Table 72. Human Stem Cells Institute Gene Therapy On Cardiovascular Disease Product and Solutions
   Table 73. Human Stem Cells Institute Gene Therapy On Cardiovascular Disease Revenue (USD Million), Gross Margin and Market Share (2018-2023)
   Table 74. Human Stem Cells Institute Recent Developments and Future Plans
   Table 75. Global Gene Therapy On Cardiovascular Disease Revenue (USD Million) by Players (2018-2023)
   Table 76. Global Gene Therapy On Cardiovascular Disease Revenue Share by Players (2018-2023)
   Table 77. Breakdown of Gene Therapy On Cardiovascular Disease by Company Type (Tier 1, Tier 2, and Tier 3)
   Table 78. Market Position of Players in Gene Therapy On Cardiovascular Disease, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
   Table 79. Head Office of Key Gene Therapy On Cardiovascular Disease Players
   Table 80. Gene Therapy On Cardiovascular Disease Market: Company Product Type Footprint
   Table 81. Gene Therapy On Cardiovascular Disease Market: Company Product Application Footprint
   Table 82. Gene Therapy On Cardiovascular Disease New Market Entrants and Barriers to Market Entry
   Table 83. Gene Therapy On Cardiovascular Disease Mergers, Acquisition, Agreements, and Collaborations
   Table 84. Global Gene Therapy On Cardiovascular Disease Consumption Value (USD Million) by Type (2018-2023)
   Table 85. Global Gene Therapy On Cardiovascular Disease Consumption Value Share by Type (2018-2023)
   Table 86. Global Gene Therapy On Cardiovascular Disease Consumption Value Forecast by Type (2024-2029)
   Table 87. Global Gene Therapy On Cardiovascular Disease Consumption Value by Application (2018-2023)
   Table 88. Global Gene Therapy On Cardiovascular Disease Consumption Value Forecast by Application (2024-2029)
   Table 89. North America Gene Therapy On Cardiovascular Disease Consumption Value by Type (2018-2023) & (USD Million)
   Table 90. North America Gene Therapy On Cardiovascular Disease Consumption Value by Type (2024-2029) & (USD Million)
   Table 91. North America Gene Therapy On Cardiovascular Disease Consumption Value by Application (2018-2023) & (USD Million)
   Table 92. North America Gene Therapy On Cardiovascular Disease Consumption Value by Application (2024-2029) & (USD Million)
   Table 93. North America Gene Therapy On Cardiovascular Disease Consumption Value by Country (2018-2023) & (USD Million)
   Table 94. North America Gene Therapy On Cardiovascular Disease Consumption Value by Country (2024-2029) & (USD Million)
   Table 95. Europe Gene Therapy On Cardiovascular Disease Consumption Value by Type (2018-2023) & (USD Million)
   Table 96. Europe Gene Therapy On Cardiovascular Disease Consumption Value by Type (2024-2029) & (USD Million)
   Table 97. Europe Gene Therapy On Cardiovascular Disease Consumption Value by Application (2018-2023) & (USD Million)
   Table 98. Europe Gene Therapy On Cardiovascular Disease Consumption Value by Application (2024-2029) & (USD Million)
   Table 99. Europe Gene Therapy On Cardiovascular Disease Consumption Value by Country (2018-2023) & (USD Million)
   Table 100. Europe Gene Therapy On Cardiovascular Disease Consumption Value by Country (2024-2029) & (USD Million)
   Table 101. Asia-Pacific Gene Therapy On Cardiovascular Disease Consumption Value by Type (2018-2023) & (USD Million)
   Table 102. Asia-Pacific Gene Therapy On Cardiovascular Disease Consumption Value by Type (2024-2029) & (USD Million)
   Table 103. Asia-Pacific Gene Therapy On Cardiovascular Disease Consumption Value by Application (2018-2023) & (USD Million)
   Table 104. Asia-Pacific Gene Therapy On Cardiovascular Disease Consumption Value by Application (2024-2029) & (USD Million)
   Table 105. Asia-Pacific Gene Therapy On Cardiovascular Disease Consumption Value by Region (2018-2023) & (USD Million)
   Table 106. Asia-Pacific Gene Therapy On Cardiovascular Disease Consumption Value by Region (2024-2029) & (USD Million)
   Table 107. South America Gene Therapy On Cardiovascular Disease Consumption Value by Type (2018-2023) & (USD Million)
   Table 108. South America Gene Therapy On Cardiovascular Disease Consumption Value by Type (2024-2029) & (USD Million)
   Table 109. South America Gene Therapy On Cardiovascular Disease Consumption Value by Application (2018-2023) & (USD Million)
   Table 110. South America Gene Therapy On Cardiovascular Disease Consumption Value by Application (2024-2029) & (USD Million)
   Table 111. South America Gene Therapy On Cardiovascular Disease Consumption Value by Country (2018-2023) & (USD Million)
   Table 112. South America Gene Therapy On Cardiovascular Disease Consumption Value by Country (2024-2029) & (USD Million)
   Table 113. Middle East & Africa Gene Therapy On Cardiovascular Disease Consumption Value by Type (2018-2023) & (USD Million)
   Table 114. Middle East & Africa Gene Therapy On Cardiovascular Disease Consumption Value by Type (2024-2029) & (USD Million)
   Table 115. Middle East & Africa Gene Therapy On Cardiovascular Disease Consumption Value by Application (2018-2023) & (USD Million)
   Table 116. Middle East & Africa Gene Therapy On Cardiovascular Disease Consumption Value by Application (2024-2029) & (USD Million)
   Table 117. Middle East & Africa Gene Therapy On Cardiovascular Disease Consumption Value by Country (2018-2023) & (USD Million)
   Table 118. Middle East & Africa Gene Therapy On Cardiovascular Disease Consumption Value by Country (2024-2029) & (USD Million)
   Table 119. Gene Therapy On Cardiovascular Disease Raw Material
   Table 120. Key Suppliers of Gene Therapy On Cardiovascular Disease Raw Materials

List of Figures

   Figure 1. Gene Therapy On Cardiovascular Disease Picture
   Figure 2. Global Gene Therapy On Cardiovascular Disease Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
   Figure 3. Global Gene Therapy On Cardiovascular Disease Consumption Value Market Share by Type in 2022
   Figure 4. Viral Gene Therapy
   Figure 5. Non-Viral Gene Therapy
   Figure 6. Global Gene Therapy On Cardiovascular Disease Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
   Figure 7. Gene Therapy On Cardiovascular Disease Consumption Value Market Share by Application in 2022
   Figure 8. Heart Disease Picture
   Figure 9. Vascular Disease Picture
   Figure 10. Global Gene Therapy On Cardiovascular Disease Consumption Value, (USD Million): 2018 & 2022 & 2029
   Figure 11. Global Gene Therapy On Cardiovascular Disease Consumption Value and Forecast (2018-2029) & (USD Million)
   Figure 12. Global Market Gene Therapy On Cardiovascular Disease Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
   Figure 13. Global Gene Therapy On Cardiovascular Disease Consumption Value Market Share by Region (2018-2029)
   Figure 14. Global Gene Therapy On Cardiovascular Disease Consumption Value Market Share by Region in 2022
   Figure 15. North America Gene Therapy On Cardiovascular Disease Consumption Value (2018-2029) & (USD Million)
   Figure 16. Europe Gene Therapy On Cardiovascular Disease Consumption Value (2018-2029) & (USD Million)
   Figure 17. Asia-Pacific Gene Therapy On Cardiovascular Disease Consumption Value (2018-2029) & (USD Million)
   Figure 18. South America Gene Therapy On Cardiovascular Disease Consumption Value (2018-2029) & (USD Million)
   Figure 19. Middle East and Africa Gene Therapy On Cardiovascular Disease Consumption Value (2018-2029) & (USD Million)
   Figure 20. Global Gene Therapy On Cardiovascular Disease Revenue Share by Players in 2022
   Figure 21. Gene Therapy On Cardiovascular Disease Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
   Figure 22. Global Top 3 Players Gene Therapy On Cardiovascular Disease Market Share in 2022
   Figure 23. Global Top 6 Players Gene Therapy On Cardiovascular Disease Market Share in 2022
   Figure 24. Global Gene Therapy On Cardiovascular Disease Consumption Value Share by Type (2018-2023)
   Figure 25. Global Gene Therapy On Cardiovascular Disease Market Share Forecast by Type (2024-2029)
   Figure 26. Global Gene Therapy On Cardiovascular Disease Consumption Value Share by Application (2018-2023)
   Figure 27. Global Gene Therapy On Cardiovascular Disease Market Share Forecast by Application (2024-2029)
   Figure 28. North America Gene Therapy On Cardiovascular Disease Consumption Value Market Share by Type (2018-2029)
   Figure 29. North America Gene Therapy On Cardiovascular Disease Consumption Value Market Share by Application (2018-2029)
   Figure 30. North America Gene Therapy On Cardiovascular Disease Consumption Value Market Share by Country (2018-2029)
   Figure 31. United States Gene Therapy On Cardiovascular Disease Consumption Value (2018-2029) & (USD Million)
   Figure 32. Canada Gene Therapy On Cardiovascular Disease Consumption Value (2018-2029) & (USD Million)
   Figure 33. Mexico Gene Therapy On Cardiovascular Disease Consumption Value (2018-2029) & (USD Million)
   Figure 34. Europe Gene Therapy On Cardiovascular Disease Consumption Value Market Share by Type (2018-2029)
   Figure 35. Europe Gene Therapy On Cardiovascular Disease Consumption Value Market Share by Application (2018-2029)
   Figure 36. Europe Gene Therapy On Cardiovascular Disease Consumption Value Market Share by Country (2018-2029)
   Figure 37. Germany Gene Therapy On Cardiovascular Disease Consumption Value (2018-2029) & (USD Million)
   Figure 38. France Gene Therapy On Cardiovascular Disease Consumption Value (2018-2029) & (USD Million)
   Figure 39. United Kingdom Gene Therapy On Cardiovascular Disease Consumption Value (2018-2029) & (USD Million)
   Figure 40. Russia Gene Therapy On Cardiovascular Disease Consumption Value (2018-2029) & (USD Million)
   Figure 41. Italy Gene Therapy On Cardiovascular Disease Consumption Value (2018-2029) & (USD Million)
   Figure 42. Asia-Pacific Gene Therapy On Cardiovascular Disease Consumption Value Market Share by Type (2018-2029)
   Figure 43. Asia-Pacific Gene Therapy On Cardiovascular Disease Consumption Value Market Share by Application (2018-2029)
   Figure 44. Asia-Pacific Gene Therapy On Cardiovascular Disease Consumption Value Market Share by Region (2018-2029)
   Figure 45. China Gene Therapy On Cardiovascular Disease Consumption Value (2018-2029) & (USD Million)
   Figure 46. Japan Gene Therapy On Cardiovascular Disease Consumption Value (2018-2029) & (USD Million)
   Figure 47. South Korea Gene Therapy On Cardiovascular Disease Consumption Value (2018-2029) & (USD Million)
   Figure 48. India Gene Therapy On Cardiovascular Disease Consumption Value (2018-2029) & (USD Million)
   Figure 49. Southeast Asia Gene Therapy On Cardiovascular Disease Consumption Value (2018-2029) & (USD Million)
   Figure 50. Australia Gene Therapy On Cardiovascular Disease Consumption Value (2018-2029) & (USD Million)
   Figure 51. South America Gene Therapy On Cardiovascular Disease Consumption Value Market Share by Type (2018-2029)
   Figure 52. South America Gene Therapy On Cardiovascular Disease Consumption Value Market Share by Application (2018-2029)
   Figure 53. South America Gene Therapy On Cardiovascular Disease Consumption Value Market Share by Country (2018-2029)
   Figure 54. Brazil Gene Therapy On Cardiovascular Disease Consumption Value (2018-2029) & (USD Million)
   Figure 55. Argentina Gene Therapy On Cardiovascular Disease Consumption Value (2018-2029) & (USD Million)
   Figure 56. Middle East and Africa Gene Therapy On Cardiovascular Disease Consumption Value Market Share by Type (2018-2029)
   Figure 57. Middle East and Africa Gene Therapy On Cardiovascular Disease Consumption Value Market Share by Application (2018-2029)
   Figure 58. Middle East and Africa Gene Therapy On Cardiovascular Disease Consumption Value Market Share by Country (2018-2029)
   Figure 59. Turkey Gene Therapy On Cardiovascular Disease Consumption Value (2018-2029) & (USD Million)
   Figure 60. Saudi Arabia Gene Therapy On Cardiovascular Disease Consumption Value (2018-2029) & (USD Million)
   Figure 61. UAE Gene Therapy On Cardiovascular Disease Consumption Value (2018-2029) & (USD Million)
   Figure 62. Gene Therapy On Cardiovascular Disease Market Drivers
   Figure 63. Gene Therapy On Cardiovascular Disease Market Restraints
   Figure 64. Gene Therapy On Cardiovascular Disease Market Trends
   Figure 65. Porters Five Forces Analysis
   Figure 66. Manufacturing Cost Structure Analysis of Gene Therapy On Cardiovascular Disease in 2022
   Figure 67. Manufacturing Process Analysis of Gene Therapy On Cardiovascular Disease
   Figure 68. Gene Therapy On Cardiovascular Disease Industrial Chain
   Figure 69. Methodology
   Figure 70. Research Process and Data Source